Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May; 35(4):359-66.

View in: PubMed

subject areas

Adjuvants, Immunologic
Aged
Aged, 80 and over
Cancer Vaccines
Female
gp100 Melanoma Antigen
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Kaplan-Meier Estimate
Male
MART-1 Antigen
Melanoma
Middle Aged
Monophenol Monooxygenase
Neoplasm Metastasis
Oligodeoxyribonucleotides
Treatment Outcome
Vaccines, Subunit

authors with profiles

JOHN KIRKWOOD